Fox Chase Cancer Center’s Jonathan Chernoff Awarded Pennsylvania Breast Cancer Coalition Grant

Article

In Partnership With:

Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase Cancer Center, was recently awarded a $50,000 grant from the Pennsylvania Breast Cancer Coalition.

Pennsylvania Breast Cancer Coalition

Pennsylvania Breast Cancer Coalition

PHILADELPHIA (February 17, 2022)— Jonathan Chernoff, MD, PhD, Cancer Center Director at Fox Chase Cancer Center, was recently awarded a $50,000 grant from the Pennsylvania Breast Cancer Coalition.

This one-year grant will provide funding for Chernoff’s research into two specific genes on chromosome 11 that become amplified in many breast cancer patients. “This grant will allow me to pursue promising preliminary data that points to new strategies for treating breast cancer. It could lead to new therapeutic approaches in a significant number of breast cancer patients,” said Chernoff, who is also the Stanley P. Reimann Chair in Oncology Research at Fox Chase.

Chernoff’s lab focuses on uncovering the roles of protein phosphorylation in governing two fundamental aspects of cancer biology—cell proliferation and cell movement. 

“Studying genetics is vitally important to the future of targeted therapies for breast cancer, and the Pennsylvania Breast Cancer Coalition (PBCC) is proud to contribute to Dr. Chernoff’s outstanding research at Fox Chase,” said PBCC President and Founder Pat Halpin-Murphy. “It is our hope that, with the help of this $50,000 grant, Dr. Chernoff’s lab is able to gather data that will one day lead to new treatments for breast cancer. Congratulations, Dr. Chernoff, and thank you for your commitment to our goal of finding a cure now… so our daughters don’t have to.”

Founded in 1933, the Pennsylvania Breast Cancer Coalition has contributed over $4.3 million to breast cancer researchers in Pennsylvania. In addition to providing funding for researchers, the Pennsylvania Breast Cancer Coalition works to support the enactment of legislation that can help save women’s lives. They also provide resources and information by sending thousands of free “Friends Like Me” care packages to newly diagnosed women. Their mission as a group is to help find a cure for breast cancer so that future generations will not face a similar diagnosis.

***

About Fox Chase Cancer Center

The Hospital of Fox Chase Cancer Center and its affiliates (collectively “Fox Chase Cancer Center”), a member of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence five consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship and community outreach. It is the policy of Fox Chase Cancer Center, that no one shall be excluded from or denied the benefits of or participation in the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

Related Videos
Video 5 - "AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes"
Rita Nanda, MD
Siddartha Yadav, MD, FACP
Nan Chen, MD
Video 4 - "The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer"
Margaret E. Gatti-Mays, MD, MPH, FACP, of The Ohio State University Comprehensive Cancer Center
Ko Un “Clara” Park, MD
Erin Frances Cobain, MD
Video 3 - "5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer"
Carlos Arteaga, MD